Venetoclax (ABT-199/GDC0199) was the first-in-class BCL2 inhibitor approved for the therapy of chronic lymphocytic leukemia, and, recently, of acute myeloid leukemia (see Section 9). Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.